2 weeks ago
Molbio Diagnostics IPO Monday debut; GMP, experts signal gains
Molbio Diagnostics is a company that makes quick medical tests to find out if people are sick.
The company sold a part of itself to the public in a process called an IPO, so many people can own a tiny piece of it.
The offer was very popular — people wanted 70 times more shares than were available.
On Monday, 17 August, these shares will start selling on two big Indian stock markets for the first time.
Before the stock market opens, people who guess share prices think the shares could be worth about ₹932, which is more than the ₹807 that buyers paid.
Experts think the shares may jump 14 to 16 percent on the first day.
The money from the sale will be used to build a research lab, buy machines, and help the company grow in places like Goa and Visakhapatnam.
Some experts say people who plan to keep the shares for years should hold on to them, while others say quick traders might take some profit on the first day.
The company's earnings have grown from about ₹836 crore to ₹1,445 crore in a few years.
Molbio Diagnostics' IPO will list on the NSE and BSE on Monday, 17 August, after being subscribed 70.26 times.
The latest grey market premium stood at ₹125, implying a potential listing price of ₹932, about 15.49% above the ₹807 issue price.
Market experts predict the stock will list at a 14–16% premium on Monday.
The issue comprised a ₹200 crore fresh issue and an offer for sale of 91.66 lakh shares worth ₹739.70 crore.
Proceeds will fund an R&D facility through subsidiary Bigtec, office-space capex, and equipment for Molbio's units in Goa and Visakhapatnam.
- Who
- Molbio Diagnostics, a point-of-care diagnostics company, and investors who bid for its IPO.
- What
- The company's shares will make their stock market debut on the NSE and BSE after the IPO was subscribed 70.26 times.
- Where
- The National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.
- When
- Monday, 17 August; the IPO bidding ran from 10–12 August and allotment was finalised on 13 August.
- Why
- The listing follows strong IPO demand, with net proceeds to be used for an R&D facility, capital expenditure and general corporate purposes.
Long-term investors
Short-term traders
Post-listing investment strategy
Long-term investors
Given the attractive long-term growth opportunity, long-term investors may consider holding the stock with a multi-year perspective.
Short-term traders
Considering the elevated IPO valuation, short-term investors may book partial gains at the expected 14–16% listing gain, while fresh investors are advised to wait for post-listing price stabilization and valuation comfort.
Key facts
- Listing date
- Monday, 17 August
- Exchanges
- NSE and BSE
- Overall subscription
- 70.26 times (QIBs 186.39x, NIIs 49.80x, retail 12.96x)
- Issue price
- ₹807 (price band ₹768–₹807)
- Grey market premium
- ₹125 (implied listing price ₹932, ~15.49% premium)
- Fresh issue / OFS
- ₹200 crore fresh issue; OFS of 91.66 lakh shares worth ₹739.70 crore
- Revenue from operations
- ₹836.56 crore (FY24), ₹1,020.42 crore (FY25), ₹1,445.69 crore (FY26)
Quotes
Harshal Dasani
Business Head – INVasset PMS
“"The market will increasingly focus on whether Molbio can sustain its growth, deepen recurring test‑kit revenues, scale its international business and convert R&D into commercially successful products. For us, this is a credible diagnostics franchise, but the durability of returns from here will depend far more on earnings delivery than on listing‑day momentum."”
livemint.com
“"However, considering the elevated IPO valuation, short‑term investors may consider booking partial gains if the stock delivers the expected 14–16% listing gain. Fresh investors are advised to wait for post‑listing price stabilization and valuation comfort before taking a fresh position."”
livemint.com







